1008-91-9

Basic information

• Product Name: 1-(4-Pyridyl)piperazine
• Synonyms: 1-(4-Pyridyl)piperazine >=97.0% (GC);4-PIPERAZINOPYRIDINE;1-PYRIDIN-4-YL-PIPERAZINE;1-(4-PYRIDINYL)PIPERAZINE;1-(4-PYRIDYL)PIPERAZINE;LABOTEST-BB LT00233138;BUTTPARK 82\08-09;RARECHEM AH CK 0194
• CAS NO: 1008-91-9
• Molecular Formula: C₉H₁₃N₃
• Molecular Weight: 163.22
• EINECS: 213-764-7
• Product Categories: Amines and Anilines;Heterocycles;pharmacetical
• Mol File: 1008-91-9.mol

Chemical Properties

• Melting Point: 137-141 °C
• Boiling Point: 195-200°C 0,3mm
• Flash Point: 195-200°C/0.3mm
• Appearance: Gray power
• Density: 1.081 g/cm³
• Refractive Index: 1.576
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• Solubility: soluble in Methanol
• PKA: 10.73±0.10(Predicted)
• Water Solubility: Soluble in water.
• Sensitive: Air Sensitive
• BRN: 609705
• CAS DataBase Reference: 1-(4-Pyridyl)piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-Pyridyl)piperazine(1008-91-9)
• EPA Substance Registry System: 1-(4-Pyridyl)piperazine(1008-91-9)

Safety Data

• Hazard Codes: C,Xi
• Statements: 34-36/37/38
• Safety Statements: 26-36/37/39-45-36-37/38/39
• RIDADR: UN 3259 8/PG 2
• WGK Germany: 3
• F: 10-34
• HazardClass: 8
• PackingGroup: II
• Hazardous Substances Data: 1008-91-9(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
1-(4-Pyridyl)piperazine is used as a key intermediate for the synthesis of various organic compounds, contributing to the development of new chemical entities with potential applications in different industries.
Used in Pharmaceutical Industry:
1-(4-Pyridyl)piperazine is used as a building block for the development of medicinally important active molecules, playing a crucial role in the creation of new drugs and therapies to treat various health conditions.
Used in Agrochemicals:
1-(4-Pyridyl)piperazine is used as a vital component in the production of agrochemicals, such as pesticides and fertilizers, to enhance crop protection and improve agricultural productivity.
Used in the Production of 1-Pyridin-4-yl-4-(4-Vinyl-Benzyl)-Piperazine:
1-(4-Pyridyl)piperazine is used as a reactant to produce 1-pyridin-4-yl-4-(4-vinyl-benzyl)-piperazine with 1-(chloromethyl)-4-vinylbenzene by heating, which can be further utilized in the synthesis of other valuable compounds.

InChI:InChI=1/C5H5NO3S/c7-10(8,9)5-1-3-6-4-2-5/h1-4H,(H,7,8,9)

Upstream product

• 63980-43-8 1-benzyl-4-(4'-pyridinyl)piperazine 
• 110-85-0 piperazine 
• 1120-87-2 4-bromopyridin 
• 626-61-9 4-Chloropyridine 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 7379-35-3 4-chlorpyridine hydrochloride 
• 1143575-84-1 2-chloro-N-(tetrahydro-2H-pyran-4-yl)-6,7-dihydrothieno[3,2-d]pyrimidin-4-amine 
• 1143575-82-9 (R)-2-(2-chloro-6,7-dihydro-thieno[3,2-d]pyrimidin-4-ylamino)-3-methyl-butan-1-ol 
• 1143575-85-2 (2-chloro-5-oxo-6,7-dihydro-5H-5λ⁴-thieno[3,2-d]pyrimidin-4-yl)-(tetrahydropyran-4-yl)-amine 
• 1143575-87-4 [1-(2-chloro-5-oxo-6,7-dihydro-5H-5λ⁴-thieno[3,2-d]pyrimidin-4-ylamino)-cyclopropyl]-methanol 
• 1143575-83-0 (R)-2-(2-chloro-5-oxo-6,7-dihydro-5H-5λ⁴-thieno[3,2-d]pyrimidin-4-ylamino)-3-methyl-butan-1-ol 
• 74901-69-2 2,4-dichloro-6,7-dihydro-thieno[3,2-d]pyrimidine 

Downstream Products

• 57260-41-0 5-phenyl-2-(4-pyridin-4-yl-piperazin-1-yl)-oxazol-4-one 
• 329004-01-5 1-[2-(4-nitro-phenyl)-ethyl]-4-pyridin-4-yl-piperazine 
• 211820-01-8 (4-(4-fluorophenylsulfonyl)piperazin-1-yl)(4-(pyridin-4-yl)piperazin-1-yl)methanone 
• 211819-99-7 1-(4-bromophenylsulphonyl)-4-[1-(pyridin-4-yl)piperazin-4-ylcarbonyl]piperazine 
• 211820-00-7 1-(4-trifluoromethylphenylsulphonyl)-4-[1-(pyridin-4-yl)piperazin-4-ylcarbonyl]piperazine 
• 533923-06-7 [6-oxo-6-(4-pyridin-4-yl-piperazin-1-yl)-hexyl]-carbamic acid tert-butyl ester 
• 112940-39-3 1-(4-nitro-phenyl)-4-pyridin-4-yl-piperazine 
• 575489-32-6 1-(4-vinylbenzyl)-4-(4-pyridyl)piperazine 
• 854159-13-0 1-(4-pyridyl)-4-tritylpiperazine 
• 162175-92-0 1-[N²-[4-amino-3,5-dibromo-N-(1-oxo-4-phenylbutyl)-D-phenylalanyl]-N⁶-(phenylmethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)piperazine 
• 204692-44-4 1-[N²-(1,1-dimethylethoxycarbonyl)-N⁶-(phenylmethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)piperazine 
• 204692-51-3 1-[N²-(phenylmethoxycarbonyl)-N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)piperazine 

Relevant articles and documents

New μ-opioid receptor agonists with piperazine moiety

New μ-opioid receptor (MOR) agonists containing piperazine and homopiperazine moieties in the structures were synthesized and their affinities to and agonist potencies on MOR were evaluated. Among the synthesized compounds, 4-[4-(2-methoxyphenyl)piperazin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide (20Aa) showed the highest affinity to the human MOR expressed in Chinese hamster ovary (CHO)-K1 cells, and the highest agonist potency on the MOR in isolated guinea-pig ileum preparation.

Acid-base properties, FT-IR, FT-Raman spectroscopy and computational study of 1-(pyrid-4-yl)piperazine

We report the vibrational spectral analysis was carried out using FT-IR and FT-Raman spectroscopy for 1-(pyrid-4-yl)piperazine (PyPi). Single crystals of PyPi suitable for X-ray structural analysis were obtained. The acid-base properties are also reported. PyPi supported on a weak acid cation-exchanger in the single protonated form and this system can be used efficiently as the solid supported analogue of 4-N,N-dimethyl-aminopyridine. The complete vibrational assignments of wavenumbers were made on the basis of potential energy distribution. The HOMO and LUMO analysis is used to determine the charge transfer within the molecule and with the molecular electrostatic potential map was applied for the reactivity assessment of PyPi molecule toward proton, electrophiles and nucleopholes as well. The stability of the molecule arising from hyper-conjugative interaction and charge delocalization has been analyzed using NBO analysis. The calculated first hyperpolarizability of PyPi is 17.46 times that of urea.

Developing Inhibitors of the p47phox-p22phox Protein-Protein Interaction by Fragment-Based Drug Discovery

Nicotinamide adenine dinucleotide phosphate oxidase isoform 2 is an enzyme complex, which generates reactive oxygen species and contributes to oxidative stress. The p47phox-p22phox interaction is critical for the activation of the catalytical NOX2 domain, and p47phox is a potential target for therapeutic intervention. By screening 2500 fragments using fluorescence polarization and a thermal shift assay and validation by surface plasmon resonance, we found eight hits toward the tandem SH3 domain of p47phox (p47phoxSH3A-B) with KD values of 400-600 μM. Structural studies revealed that fragments 1 and 2 bound two separate binding sites in the elongated conformation of p47phoxSH3A-B and these competed with p22phox for binding to p47phoxSH3A-B. Chemical optimization led to a dimeric compound with the ability to potently inhibit the p47phoxSH3A-B-p22phox interaction (Ki of 20 μM). Thereby, we reveal a new way of targeting p47phox and present the first report of drug-like molecules with the ability to bind p47phox and inhibit its interaction with p22phox.

New stable Cu(I) catalyst supported on weakly acidic polyacrylate resin for green C-N coupling: Synthesis of N-(Pyridin-4-yl)benzene amines and N,N-Bis(pyridine-4-yl)benzene amines

A method for preparation of a new stable Cu(I) catalyst supported on weakly acidic polyacrylate resin without additional stabilizing ligands is described. A simple and efficient methodology for Ullmann Cu(I) catalyzed C-N cross coupling reactions using this original catalyst is reported. Coupling reactions of 4-chloropyridinium chloride with anilines containing electron donating (EDG) or electron withdrawing (EWG) groups, naphthalen-2-amine and piperazine, respectively, are successfully demonstrated.

Discovery of β2 adrenergic receptor ligands using biosensor fragment screening of tagged wild-type receptor

G-protein coupled receptors (GPCRs) are the primary target class of currently marketed drugs, accounting for about a quarter of all drug targets of approved medicines. However, almost all the screening efforts for novel ligand discovery rely exclusively on cellular systems overexpressing the receptors. An alternative ligand discovery strategy is a fragment-based drug discovery, where low molecular weight compounds, known as fragments, are screened as initial starting points for optimization. However, the screening of fragment libraries usually employs biophysical screening methods, and as such, it has not been routinely applied to membrane proteins. We present here a surface plasmon resonance biosensor approach that enables, cell-free, label-free, fragment screening that directly measures fragment interactions with wild-type GPCRs. We exemplify the method by the discovery of novel, selective, high affinity antagonists of human β2 adrenoceptor.

DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS

The present invention relates to new drug combinations which contain in addition to one or more PDE4-inhibitors at least one NSAID (=non-steroidal anti-inflammatory drug) (2), processes for preparing them and their use in treating in particular respiratory complaints such as for example COPD, chronic sinusitis and asthma. The invention particularly relates to those drug combinations which, in addition to one or more, preferably one PDE4 inhibitor of general formula 1 wherein X is SO or SO2, but preferably SO, and wherein R3 denotes an optionally substituted, mono- or bicyclic, unsaturated, partly saturated or saturated heterocyclic group or an optionally substituted, mono- or bicyclic heteroaryl and wherein R1 and R2 have the meanings given in claim 1, contain at least one NSAID (2), the preparation thereof and the use thereof for the treatment of respiratory complaints.

4-Aryl piperazine and piperidine amides as novel mGluR5 positive allosteric modulators

Positive allosteric modulation of metabotropic glutamate receptor 5 (mGluR5) is regarded as a potential novel treatment for schizophrenic patients. Herein we report the synthesis and SAR of 4-aryl piperazine and piperidine amides as potent mGluR5 positive allosteric modulators (PAMs). Several analogs have excellent activity and desired drug-like properties. Compound 2b was further characterized as a PAM using several in vitro experiments, and produced robust activity in several preclinical animal models.

Substituted Disulfonamide Compounds

Substituted disulfonamide compounds corresponding to formula I: In which R1, R2, R3, R4a, R4b, R5a, R5b, R8, R9a, R9b, R10, R11, a, b, s, t and A have defined meanings, pharmaceutical compositions containing one or more such compounds, processes for preparing such compounds, and a method of using such compounds for the treatment or inhibition of pain and/or other conditions mediated by the bradykinin receptor 1 (BR1).

SUBSTITUTED SULFONAMIDE DERIVATIVES

The invention relates to substituted sulfonamide derivatives, processes for the preparation thereof, medicaments containing these compounds and the use of substituted sulfonamide derivatives for the preparation of medicaments.

Discovery of a novel CCR5 antagonist lead compound through fragment assembly

CCR5, as the major co-receptor for HIV-1 entry, is an attractive novel target for the pharmaceutical industry in the HIV-1 therapeutic area. In this study, based on the structures of maraviroc and 1,4-bis(4-(7-chloroquinolin-4- yl)piperazin-1-yl)butane-1,4-dione (1), which was identified using structure-based virtual screening in conjunction with a calcium mobilization assay, a series of novel small molecule CCR5 antagonists have been designed and synthesized through fragment assembly. Preliminary SARs were obtained, which are in good agreement with the molecular binding model and should prove helpful for future antagonist design. The novel scaffold presented here might also be useful in the development of maraviroc-derived second generation CCR5 antagonists.